Nanomedicine
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 45 (10), 965-988
- https://doi.org/10.2165/00003088-200645100-00002
Abstract
The intricate problems associated with the delivery and various unnecessary in vivo transitions of proteins and drugs needs to be tackled soon to be able to exploit the myriad of putative therapeutics created by the biotechnology boom. Nanomedicine is one of the most promising applications of nanotechnology in the field of medicine. It has been defined as the monitoring, repair, construction and control of human biological systems at the molecular level using engineered nanodevices and nanostructures. These nanostructured medicines will eventually turn the world of drug delivery upside down. PEGylation (i.e. the attachment of polyethylene glycol to proteins and drugs) is an upcoming methodology for drug development and it has the potential to revolutionise medicine by drastically improving the pharmacokinetic and pharmacodynamic properties of the administered drug. This article provides a total strategy for improving the therapeutic efficacy of various biotechnological products in drug delivery. This article also presents an extensive analysis of most of the PEGylated proteins, peptides and drugs, together with extensive clinical data. Nanomedicines and PEGylation, the latest offshoots of nanotechnology will definitely pave a way in the field of drug delivery where targeted delivery, formulation, in vivo stability and retention are the major challenges.Keywords
This publication has 172 references indexed in Scilit:
- Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugatesAdvanced Drug Delivery Reviews, 2003
- Identification of tumour-associated t-cell epitopes for vaccine developmentNature Reviews Cancer, 2002
- PegylationClinical Pharmacokinetics, 2001
- Apoptosis by Death FactorCell, 1997
- Biodegradable Long-Circulating Polymeric NanospheresScience, 1994
- Hepatic excretion and metabolism of polyethylene glycols and mannitol in the catJournal of Hepatology, 1993
- Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol.CHEMICAL & PHARMACEUTICAL BULLETIN, 1990
- Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene glycol-modified adenosine deaminaseThe Journal of Pediatrics, 1988
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987
- Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalaseJournal of Free Radicals in Biology & Medicine, 1986